Table 2.
Joint effect survival analysis of clinical factors and the risk score with OS in PDAC patients
| Group | Risk score | Variables | Events/total (n=112) | MST (days) | Crude HR (95% CI) | Crude P | Adjusted HR (95% CI) | Adjusted P£ |
|---|---|---|---|---|---|---|---|---|
| Histological grade | ||||||||
| A | Low risk | G1+G2 | 20/42 | 913 | 1 | 1 | ||
| B | Low risk | G3+G4 | 9/14 | 592 | 2.068 (0.907–4.714) | 0.084 | 2.431 (0.961–6.151) | 0.061 |
| C | High risk | G1+G2 | 25/38 | 366 | 6.105 (3.047–12.230) | <0.0001 | 5.012 (2.286–10.987) | <0.0001 |
| D | High risk | G3+G4 | 15/18 | 278 | 10.088 (4.689–21.703) | <0.0001 | 7.276 (3.071–17.236) | <0.0001 |
| Radiation therapy* | ||||||||
| a | Low risk | No | 15/30 | 695 | 1 | 1 | ||
| b | Low risk | Yes | 11/20 | 702 | 1.164 (0.511–2.653) | 0.717 | 1.190 (0.491–2.885) | 0.701 |
| c | High risk | No | 33/40 | 250 | 7.696 (3.680–16.092) | <0.0001 | 4.661 (2.084–10.424) | 0.0002 |
| d | High risk | Yes | 4/10 | NA | 3.127 (0.947–10.327) | 0.061 | 4.536 (1.279–16.093) | 0.019 |
| Radical resection& | ||||||||
| I | Low risk | R0 | 19/36 | 738 | 1 | 1 | ||
| II | Low risk | R1/RX | 9/18 | 592 | 2.302 (0.978–5.417) | 0.056 | 2.271 (0.885–5.828) | 0.088 |
| III | High risk | R0 | 20/30 | 366 | 7.464 (3.416–16.310) | <0.0001 | 5.651 (2.291–13.937) | <0.0001 |
| IV | High risk | R1/RX | 20/26 | 278 | 8.453 (3.973–17.984) | <0.0001 | 7.654 (3.188–18.374) | <0.0001 |
| Targeted molecular | ||||||||
| therapy‡ | ||||||||
| i | Low risk | Yes | 24/46 | 702 | 1 | 1 | ||
| ii | Low risk | No | 3/5 | 467 | 3.819 (1.087–13.420) | 0.037 | 4.781 (1.209–18.910) | 0.026 |
| iii | High risk | Yes | 17/27 | 458 | 4.489 (2.160–9.328) | <0.0001 | 4.431 (1.951–10.062) | <0.0001 |
| iv | High risk | No | 21/24 | 160 | 17.254 (8.015–37.145) | <0.0001 | 20.942 (8.089–54.217) | <0.0001 |
Notes: “Events” means the numbers of patients who had died.
£
Adjusted for histologic grade, radiation therapy, radical resection, and targeted molecular therapy.
*
Radiation therapy information is unavailable in 12 patients.
&
Radical resection information is unavailable in two patients.
‡
Targeted molecular therapy information is unavailable in 10 patients.
Abbreviations: OS, overall survival; PDAC, pancreatic ductal adenocarcinoma; MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval; NA, not available.